Protagonist Therapeutics Presents Phase 2b Trial Data for Icotrokinra

Protagonist Therapeutics, based in Newark, California, announced that its Phase 2b ANTHEM-UC trial results will be presented at the United European Gastroenterology Week 2025 in Berlin. The presentation, led by Dr. Maria Abreu from Cedars-Sinai Medical Center, will focus on icotrokinra, a peptide targeting the IL-23 receptor in ulcerative colitis. Scheduled for October 7, 2025, the talk will discuss week 12 results of the randomized, placebo-controlled trial.

Icotrokinra is a first-in-class oral peptide developed in collaboration with J&J Innovative Medicines. The drug aims to treat moderately to severely active ulcerative colitis by selectively blocking IL-23R activation. Abstracts for the presentation are currently available on the UEGW website.

Protagonist also has other drug candidates in development, including rusfertide for polycythemia vera, co-developed with Takeda. The company continues to expand its pipeline, addressing validated targets in its pre-clinical programs.